Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119822
Chunk: 30

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 30
---
4 Securities | 10,544,959 shares of Common Stock (based on total shares outstanding as of March 31, 2025). |

| Use of proceeds | We intend to use the net proceeds from the exercise of the 2024 Warrants for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures,           
 regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. We estimate that the 
 gross proceeds to us from the exercise of the 2024 Warrants will be approximately $77.8 million, to the extent the exercise prices therefor are paid in cash. See “Use of Proceeds” elsewhere in this prospectus.                                     |

Resale of Common Stock

| Shares of Common Stock offered by the Selling Securityholder | Up to 3,250,000 shares of Common Stock, issuable upon exercise of the Deposit Warrant. |

| Use of proceeds | We will not receive any proceeds from the sale of shares of Common Stock by the Selling Securityholder, except with respect to amounts received by us upon the exercise of the Deposit Warrant for cash. We estimate that the gross proceeds to us 
 from the exercise of the Deposit Warrant will be approximately $3.9 million. See “Use of Proceeds” elsewhere in this prospectus.                                                                                                                   |

| Market for our Common Stock | Our Common Stock is listed on the Nasdaq Capital Market under the symbol “SCLX”. |

| Risk factors | See “Risk Factors” beginning on page 23 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in the securities being offered by this prospectus. |

| (1) | The number of shares of Common Stock outstanding assumes that an aggregate of 6,951,671 shares are outstanding                                                                                                                                     
 immediately prior to the completion of this offering, which number is based on an aggregate of 6,951,671 shares outstanding as of December 31, 2024, taking into account the Reverse Stock Split, with no additional shares of Common Stock issued 
 after December 31, 2024 and on or prior to March 31, 2025, and excludes:                                                                                                                                                                           |

| • |     | 18,665 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2017 Scilex                            
 Pharmaceuticals Inc. Equity In